Can I Take Ashwagandha with Fosamax (Alendronate)?

What Is the Actual Interaction Risk?

No published randomized controlled trial has tested alendronate alongside ashwagandha in the same cohort. Based on the available pharmacology, the risk is classified as theoretical and pharmacodynamic, not pharmacokinetic. Alendronate is not metabolized by cytochrome P450 enzymes, so ashwagandha's mild CYP modulation does not alter alendronate blood levels. The concern is indirect: ashwagandha changes hormonal signals that influence bone remodeling, and those changes could slightly shift the physiological background in which alendronate operates.

Why Pharmacokinetics Are Not the Problem

Alendronate is absorbed in the proximal small intestine, is not hepatically metabolized, and is excreted unchanged by the kidneys. Its oral bioavailability is already low at roughly 0.6% under fasting conditions, and this is why the prescribing information mandates taking it with plain water 30 minutes before any food, drink, or other medication. Ashwagandha contains no mineral salts, oxalates, or phytates in amounts that would chelate bisphosphonate molecules the way calcium or antacids do, so it does not reduce alendronate absorption.

Why Pharmacodynamics Deserve Attention

Bone is not static. Osteoclasts resorb old bone; osteoblasts build new bone. Alendronate works by binding to hydroxyapatite and inhibiting osteoclast-mediated resorption, reducing fracture risk by roughly 50% at the vertebrae over three years in the FIT trial (N=2,027) [1]. Ashwagandha influences three hormonal axes that intersect with this remodeling cycle: the hypothalamic-pituitary-adrenal (HPA) axis via cortisol reduction, the hypothalamic-pituitary-thyroid (HPT) axis via T3/T4 shifts, and the gonadal axis via modest testosterone increases.

How Ashwagandha Affects Cortisol and Why That Matters for Bone

Chronically elevated cortisol is a recognized driver of secondary osteoporosis. Glucocorticoid excess suppresses osteoblast activity, accelerates osteoclast recruitment, and reduces intestinal calcium absorption. The clinical syndrome of glucocorticoid-induced osteoporosis (GIOP) is well-documented, and the American College of Rheumatology guidelines recommend bisphosphonate therapy for patients on prednisone 2.5 mg or more per day for 3 or more months [2].

What the Ashwagandha Cortisol Data Actually Show

A 60-day double-blind RCT by Chandrasekhar et al. (N=64) found that 300 mg of ashwagandha root extract twice daily reduced serum cortisol by 27.9% compared to placebo (P<0.001) [3]. A 2019 RCT by Langade et al. (N=58) using 300 mg twice daily for eight weeks reported a 22.2% reduction in morning serum cortisol and significant improvements in self-reported stress scores [4].

Reducing pathologically elevated cortisol to a normal range is theoretically bone-protective and could complement alendronate's mechanism. Lowering cortisol in a person who is not hypercortisolemic is generally benign for bone. The concern only becomes real if someone has adrenal insufficiency or is on exogenous glucocorticoids at borderline doses where a cortisol-lowering supplement might alter the therapeutic balance.

Practical Implication

If you are taking alendronate specifically because of glucocorticoid-induced osteoporosis and you add ashwagandha, tell your prescriber. The cortisol reduction ashwagandha provides could change your overall glucocorticoid burden in ways that affect the risk-benefit calculation for bisphosphonate dosing duration.

Ashwagandha, Thyroid Hormones, and Bone Remodeling

The T3/T4 Evidence

Thyroid hormones directly regulate the speed of bone remodeling. Hyperthyroidism accelerates bone turnover and reduces bone density; hypothyroidism slows remodeling. Ashwagandha has been shown to modestly increase thyroid hormone output in subclinical hypothyroid populations. A 2018 RCT by Sharma et al. (N=50) found that 600 mg per day of ashwagandha root extract for eight weeks raised serum T4 by a statistically significant margin (T4 increased from a mean of 7.01 to 7.88 mcg/dL, P<0.05) and T3 similarly [5].

Implications for Alendronate Users

For patients who are euthyroid, this modest thyroid stimulation is unlikely to produce clinically meaningful changes in bone turnover. For patients with existing thyroid disease (Hashimoto thyroiditis, subclinical hyperthyroidism, or those on levothyroxine titrated to a narrow TSH range), even a small upward shift in thyroid hormone output could accelerate bone resorption. That acceleration would work against alendronate's goal of suppressing osteoclast activity.

A TSH check at baseline and at three months is a reasonable precaution if a thyroid-condition patient begins ashwagandha while on alendronate. The Endocrine Society does not yet have a specific guideline covering ashwagandha-thyroid interactions, but its 2020 clinical practice guideline on osteoporosis management emphasizes controlling secondary causes of bone loss before or alongside pharmacological therapy [6].

Ashwagandha, Testosterone, and Bone Density

What the Evidence Shows

Testosterone supports bone mineral density in both men and women. A 16-week double-blind RCT by Wankhede et al. (N=57) in healthy men found that 300 mg of ashwagandha root extract twice daily increased testosterone by 15.4% compared to placebo (P<0.05) [7]. A 2015 study published in the Journal of the International Society of Sports Nutrition showed similar effects alongside improvements in muscle mass and recovery.

In postmenopausal women, who represent the largest population prescribed alendronate for osteoporosis, testosterone levels are already low. Ashwagandha's effect on female testosterone in this demographic has been studied less rigorously than in men, so the magnitude of any benefit is uncertain.

Is a Testosterone-Boosting Supplement a Problem with Alendronate?

No. Higher testosterone, if achieved, would be additive to alendronate's bone-protective effect rather than antagonistic. The FIT trial demonstrated that alendronate reduces vertebral fracture risk independent of sex hormone levels [1]. There is no pharmacological reason why increased endogenous testosterone would blunt alendronate's bisphosphonate mechanism at the hydroxyapatite level.

Absorption and Timing: Do You Need to Separate the Doses?

Alendronate's Strict Dosing Window

Alendronate's FDA prescribing information states the tablet must be taken with 6 to 8 oz of plain water, in the morning, at least 30 minutes before the first food, beverage, or medication of the day [8]. This window protects against the dramatic bioavailability reduction caused by food, coffee, mineral water, calcium supplements, and antacids.

Where Ashwagandha Fits

Ashwagandha is commonly formulated as a root powder capsule or extract capsule. It does not contain calcium, magnesium, aluminum, or iron in amounts sufficient to chelate alendronate. Published chelation data on Withania somnifera extracts do not identify significant mineral-binding capacity. Taking ashwagandha with breakfast, well after the alendronate 30-minute window closes, is the simplest approach and eliminates any speculative absorption concern.

A Practical Morning Sequence

Wake up, take alendronate with 8 oz plain water, remain upright for 30 minutes, eat breakfast, then take ashwagandha with food. Ashwagandha's own absorption is not impaired by food; in fact, taking it with a meal reduces the mild gastrointestinal irritation some users report.

Known Alendronate Drug and Supplement Interactions to Keep in Perspective

Understanding the ashwagandha question requires knowing what actually does interact with alendronate. The interactions the FDA label flags are:

• Calcium, antacids, and multivitamins with minerals. These reduce alendronate absorption by more than 60% if taken within 30 minutes.
• NSAIDs and aspirin. Concurrent use increases upper GI adverse event risk, particularly esophageal irritation.
• Ranitidine IV (historical). Increased alendronate bioavailability by approximately 40%; no longer clinically relevant given ranitidine withdrawal.

Ashwagandha does not appear on the FDA label's interaction list, and the Natural Medicines Database currently rates the evidence for an ashwagandha-alendronate interaction as "unknown" due to absence of direct study data rather than evidence of harm.

Who Should Be Most Cautious?

Not every alendronate patient carries the same risk profile when adding ashwagandha. The following framework organizes patients by concern level:

Low concern. Postmenopausal woman with primary osteoporosis, normal thyroid function, not on glucocorticoids, no adrenal disease. Ashwagandha's hormonal effects are unlikely to meaningfully interfere with alendronate. A brief mention to the prescriber is courteous but not urgent.

Moderate concern. Patients with subclinical hypothyroidism or Hashimoto thyroiditis, or those whose osteoporosis is partially attributed to stress-related cortisol elevation. Baseline TSH and a recheck at three months are warranted. A cortisol measurement (morning serum cortisol or 24-hour urine free cortisol) may help establish whether the cortisol-lowering effect is relevant.

Higher concern. Patients on systemic glucocorticoids (prednisone, dexamethasone, or equivalent) with glucocorticoid-induced osteoporosis who are using alendronate per ACR guidelines. Adding a cortisol-modulating supplement without prescriber awareness in this group risks unpredictable shifts in the HPA axis. Get explicit sign-off first.

Do not combine without specialist review. Patients with diagnosed adrenal insufficiency on hydrocortisone replacement. Ashwagandha's HPA effects in this group are unstudied and could theoretically complicate glucocorticoid replacement dosing.

What the Guidelines Say About Osteoporosis Management and Supplements

The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation) recommends calcium 1,000 to 1,200 mg per day and vitamin D 800 to 1,000 IU per day as the nutritional foundation alongside bisphosphonate therapy. Ashwagandha is not addressed. The Endocrine Society's 2020 clinical practice guideline on osteoporosis states: "Secondary causes of bone loss should be identified and treated before or concurrently with pharmacological therapy" [6]. This framing is relevant because stress-related hypercortisolism counts as a secondary cause.

The American Association of Clinical Endocrinology's 2020 clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis similarly do not list adaptogenic herbs but emphasize that "antiresorptive therapy efficacy depends on adequate calcium and vitamin D status and the absence of uncontrolled secondary contributors to bone loss" [9].

These guidance documents do not prohibit ashwagandha. They do establish that the hormonal environment in which alendronate operates matters for outcomes.

Monitoring Plan If You Choose to Take Both

A reasonable monitoring schedule for a patient who wants to continue alendronate and add ashwagandha:

Before starting ashwagandha:

• TSH and free T4
• Morning serum cortisol (optional but useful if stress is the reason for considering ashwagandha)
• Bone-turnover markers: serum CTX (C-terminal telopeptide) as a baseline resorption marker

At 3 months:

• Repeat TSH. A rise above the upper limit of the reference range warrants holding ashwagandha and reassessing.
• Repeat serum CTX if available. Alendronate typically suppresses CTX by 50 to 70% within three months; if CTX unexpectedly remains elevated, secondary causes including new thyroid dysfunction should be investigated.

Ongoing:

• DEXA scan per standard alendronate monitoring intervals (every 1 to 2 years while on therapy per guidelines).

Ashwagandha Safety Profile Independent of Alendronate

Before combining any supplement with a prescription medication, its own safety record deserves scrutiny. Ashwagandha has a generally favorable profile in trials up to 90 days. Reported adverse events are mostly mild: GI upset, drowsiness, loose stools. Rare but documented cases of drug-induced liver injury (DILI) have been reported in the literature; a 2023 case series identified five cases of hepatotoxicity associated with Withania somnifera products, though causality was complicated by multi-ingredient supplements [10].

Liver toxicity would be clinically relevant for alendronate users only in that severe hepatic impairment can reduce protein binding and overall drug handling, though alendronate is minimally protein-bound and not hepatically metabolized. Still, any new jaundice, right upper-quadrant pain, or fatigue after starting ashwagandha warrants stopping it and checking liver function tests.

Key Takeaways for Your Prescriber Conversation

Tell your doctor or pharmacist:

• The exact ashwagandha product name, dose (typically 300 to 600 mg extract standardized to 5% withanolides per day), and why you are taking it.
• Whether you have thyroid disease, adrenal conditions, or are on any glucocorticoid.
• That you will continue the alendronate morning dosing protocol exactly as prescribed and will take ashwagandha at a separate time, typically with breakfast.

A direct prescriber conversation also allows a review of whether your current calcium and vitamin D intake meets the 1,000 to 1,200 mg / 800 to 1,000 IU daily targets, since those supplements do require strict separation from alendronate and are often underused in patients on bisphosphonates.

The FIT trial demonstrated a 47% reduction in hip fracture with alendronate at 36 months [1]. Protecting that benefit by maintaining proper dosing protocol costs nothing. Take the alendronate first, wait 30 minutes, eat, and then add the ashwagandha with food.